Exicure Inc (XCUR) |
2.07 -0.16 (-7.17%)
|
03-05 07:44 |
Open: |
2.18 |
Pre. Close: |
2.23 |
High:
|
2.26 |
Low:
|
2 |
Volume:
|
1,385,364 |
Market Cap:
|
181M |
|
|
Exicure, Inc. is a clinical-stage biotechnology company, which engages in the discovery, research, and development of treatments based on spherical nucleic acid technology (SNA). The company is headquartered in Skokie, Illinois and currently employs 33 full-time employees. The firm is focused on developing gene regulatory and immuno-oncology therapeutics-based on its proprietary spherical nucleic acid (SNA) technology. SNAs are nanoscale constructs consisting of densely packed synthetic nucleic acid sequences that are radially arranged in three dimensions. The Company’s intellectual property portfolio includes 125 pending patent applications and 45 allowed or issued patents. These filings impact numerous jurisdictions worldwide, and they cover a range of inventions, including fundamental nanoparticle manufacturing breakthroughs and numerous application-specific improvements. |
Stock Price Prediction |
Update at 5:00pm EST |
If tomorrow:
|
Open lower
|
Open higher
|
High:
|
2.261 - 2.276 |
2.276 - 2.289 |
Low:
|
1.974 - 1.987 |
1.987 - 1.998 |
Close:
|
2.05 - 2.072 |
2.072 - 2.091 |
|
Technical analysis |
as of: 2021-03-04 5:15:22 PM |
Overall:
|
|
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
Target: |
Six months: 2.94 One year: 3.31 |
Support: |
Support1: 2.00 Support2: 1.66  |
Resistance: |
Resistance1: 2.51 Resistance2: 2.83 |
Pivot: |
2.40  |
Moving Average: |
MA(5): 2.19 MA(20): 2.41 
MA(100): 1.93 MA(250): 2.07  |
MACD: |
MACD(12,26): -0.02 Signal(9): 0.04  |
Stochastic oscillator: |
%K(14,3): 15.02 %D(3): 14.40  |
RSI: |
RSI(14): 39.66  |
52-week: |
High: 3.30 Low: 0.96 Change(%): -2.4 |
Average Vol(K): |
3-Month: 60036 10-Days: 55059 |
|
Price, moving averages and Bollinger Bands |
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.XCUR has closed above bottom band by 9.4%. Bollinger Bands are 40% wider than normal. The large width of the bands suggest high volatility as compared to XCUR's normal range. The bands have been in this wide range for 1 bars. This is a sign that the current trend might continue. |
|
Headline News |
Fri, 05 Mar 2021 Exicure - Consensus Indicates Potential 340.5% Upside - DirectorsTalk Interviews
Thu, 04 Mar 2021 Analysts’ Top Services Picks: Exicure (XCUR), Wendy’s (WEN) - Smarter Analyst
Wed, 03 Mar 2021 Exicure Inc. (XCUR) Granted Orphan Drug Designation by the US Food and Drug Administration for Cavrotolimod - StreetInsider.com
Tue, 02 Mar 2021 Exicure, Inc. (XCUR) May Report Negative Earnings: Know the Trend Ahead of Q4 Release - Yahoo Finance
Mon, 15 Feb 2021 How Much Are Exicure, Inc. (NASDAQ:XCUR) Insiders Spending On Buying Shares? - Yahoo Finance
Tue, 09 Feb 2021 Exicure Announces Participation in 10th Annual SVB Leerink Global Healthcare Conference - Business Wire
|
Financial Analysis |
Growth |
 |
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
Profitability |
 |
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
Solvency |
 |
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
Efficiency |
 |
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
Return on Equity: |
Underperform |
Debt to Equity: |
Outperform |
|
|
|
|
|
Free Technical Analysis Charts
|
|
Stock Basics & Statistics |
Exchange: NASDAQ |
Sector: Healthcare |
Industry: Biotechnology |
Shares Out. (M) |
88 |
Shares Float (M) |
64 |
% Held by Insiders
|
23.33 |
% Held by Institutions
|
46.17 |
Shares Short (K)
|
1,140 |
Shares Short P. Month (K)
|
945 |
Stock Financials |
EPS
|
-0.259 |
EPS Est This Year
|
|
EPS Est Next Year
|
|
Book Value (p.s.)
|
0.840 |
Profit Margin
|
-130.87 |
Operating Margin
|
-137.55 |
Return on Assets (ttm)
|
-15.6 |
Return on Equity (ttm)
|
-31.7 |
Qtrly Rev. Growth
|
363.6 |
Gross Profit (p.s.)
|
-0.206 |
Sales Per Share
|
0.192 |
EBITDA (p.s.)
|
-0.256 |
Qtrly Earnings Growth
|
|
Operating Cash Flow (M)
|
-12 |
Levered Free Cash Flow (M)
|
-7 |
Stock Valuations |
PE Ratio
|
-7.99 |
PEG Ratio
|
|
Price to Book value
|
2.46 |
Price to Sales
|
10.81 |
Price to Cash Flow
|
-14.95 |
Stock Dividends |
Dividend
|
|
Forward Dividend
|
|
Dividend Yield
|
|
Dividend Pay Date
|
Invalid DateTime. |
Ex-Dividend Date
|
Invalid DateTime. |
7 Binary Options
|
Your Ad Here
|
|